Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)
CASRN 121-82-4 | DTXSID9024142
IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Interagency Science Consultation Draft)
Notice - This site contains archived material(s)
Archive disclaimer
Archived files are provided for reference purposes only.
The file was current when produced, but is no longer maintained and may now be outdated.
Persons with disabilities having difficulty accessing archived files may contact the Risk Webmaster for assistance.
Please use the contact us form if you need additional support.
Overview
Citation
Background
An oral reference dose (RfD) and an oral cancer slope factor are currently available on IRIS. A reassessment of the human health effects of RDX, including both cancer effects and effects other than cancer, is being undertaken.
History/Chronology
Date | Description |
---|---|
Aug 2013 | EPA released preliminary draft materials for discussion at the December IRIS Bimonthly Public Meeting. |
Dec 2013 | EPA discussed preliminary draft materials at the December 12-13, 2013 IRIS Bimonthly Public Meeting. Presentations are also available on the meeting web site. |
Sep 2014 | EPA initiated the interagency science consultation on the draft Toxicological Review of RDX. |
Mar 2016 | EPA released the public comment draft for a 60-day review period and announced it will be discussed at the May 10, 2016 IRIS Public Science Meeting. EPA also released the interagency science consultation documents, comments from reviewers, and EPA's response to major comments. [Federal Register Notice: Mar 10, 2016] |
Status
Download(s)
This download(s) is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy.
- IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) Interagency Consultation Draft (PDF) (160 pp, 2.1 MB, about PDF)
- Supplemental Information for the IRIS Toxicological Review of Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) Interagency Consultation Draft (PDF) (128 pp, 1.7 MB, about PDF)
- Charge to Reviewers - Sep 2014 (PDF) (3 pp, 108.4 KB, about PDF)
- EPA Response to Major Interagency Comments (PDF) (7 pp, 188.5 KB, about PDF)
- 1. CDC/ATSDR Comments on the RDX Interagency Consultation Draft (PDF) (2 pp, 119.1 KB, about PDF)
- 2. CEQ Comments on the RDX Interagency Consultation Draft (PDF) (1 pp, 62.5 KB, about PDF)
- 3. DoD Comments on the RDX Interagency Consultation Draft (PDF) (18 pp, 172.9 KB, about PDF)
- 4. DoD Comments on the RDX Interagency Consultation Draft (Supplemental Information Document) (PDF) (4 pp, 75.2 KB, about PDF)
- 5. DoD Comments on the RDX Interagency Consultation Draft (Charge) (PDF) (4 pp, 86.9 KB, about PDF)
- 6. NASA Comments on the RDX Interagency Consultation Draft (PDF) (1 pp, 59.6 KB, about PDF)
- 7. NIOSH Comments on the RDX Interagency Consultation Draft (PDF) (1 pp, 109.4 KB, about PDF)
- 8. NTP Comments on the RDX Interagency Consultation Draft (PDF) (4 pp, 92.8 KB, about PDF)
- 9. OMB and OSTP Comments on the RDX Interagency Consultation Draft (PDF) (5 pp, 143.6 KB, about PDF)
If you have a disability and the format of any material on our web pages interferes with your ability to access the information, please reach out to us using the Contact Us about IRIS form for assistance. To enable us to respond in a manner most helpful to you, please indicate the nature of the accessibility problem, the web address of the requested material, your preferred format in which you want to receive the material (electronic format (ASCII, etc.), standard print, large print, etc.), and your contact information.
Document Related Link(s)
- IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Preliminary Assessment Materials)
- IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (Public Comment Draft)
- IRIS Toxicological Review of Hexahydro-1,3,5-Trinitro-1,3,5-Triazine (RDX) (External Review Draft)